FAHFA Lipids for Insulin Sensitivity and Metabolic Monitoring

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods lack effective tools for monitoring and treating metabolic disorders such as obesity, type 2 diabetes, and related complications, as well as cancer, which are associated with changes in metabolic flux, and there is a need for agents that modulate key metabolic pathways.

Innovation Solution

The development of fatty acyl hydroxy acids (FAHFAs) and their derivatives, which are used to assess disease states and treatment responses by determining their levels in biological samples and administering them to increase insulin sensitivity and decrease pro-inflammatory signaling.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If current methods are used for monitoring and treating metabolic disorders, then existing treatment options are limited, but effective monitoring and treatment tools are lacking

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidavailability of monitoring and treatment tools

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent identifies FAHFAs as a universal biomarker that can monitor multiple metabolic disorders including obesity, type 2 diabetes, and cancer through a single detection approach. This multi-functional application resolves the contradiction by providing versatile monitoring capability across different disease states while maintaining reliable treatment guidance

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If FAHFAs are administered to increase insulin sensitivity, then insulin sensitivity improves, but the mechanism of action needs to be understood

Engineering Contradiction:

Improveinsulin sensitivityVSAvoidmechanism understanding

Core Design Contradiction:

ReliabilityVSLoss of information

Solution Approach 1:

The patent establishes a feedback mechanism where FAHFA levels are measured in biological samples to monitor disease state and treatment response. This feedback loop allows clinicians to adjust treatment based on measured FAHFA levels, ensuring reliable improvement in insulin sensitivity while continuously gathering information about the mechanism of action through level monitoring

Inventive Principle:

Principle #23Feedback

3Object-affected harmful factors

If FAHFAs are used to decrease pro-inflammatory signaling, then inflammation reduces, but the specific pathways affected need to be identified

Engineering Contradiction:

Improvepro-inflammatory signalingVSAvoidpathway identification

Core Design Contradiction:

Object-affected harmful factorsVSLoss of information

Solution Approach 1:

The patent positions FAHFAs as intermediary molecules that mediate between metabolic state and inflammatory response. By measuring FAHFA levels, the patent provides an indirect but reliable measure of both metabolic dysfunction and inflammatory activity, resolving the contradiction by using FAHFAs as information carriers about pathway activity without requiring direct pathway measurement

Inventive Principle:

Principle #24Intermediary (Mediator)

Data Source

PatentEP2972399B1Lipids that increase insulin sensitivity and methods of using the same

Publication Date: 2020.09.02 BETH ISRAEL DEACONESS MEDICAL CENT INC

Figure 1~2
Figure 3a~3b
Figure 4~5

AI summary

The invention provides, inter alia, fatty acyl hydroxy fatty acid (FAHFA; a novel class of estolide-related molecules) and diagnostic and treatment methods for a variety of disorders — including diabetes-related disorders, Metabolic Syndrome, polycyctic ovarian syndrome, cancer, and inflammatory disorders — using them; as well as methods of screening for additional compounds that are useful in treating these disorders and/or that modulate FAHFA levels, FAHFA-mediated signaling, and FAHFA-mediated biological effects.